Financiere des Professionnels Fonds d investissement inc. Has $5.35 Million Stake in Icon Plc $ICLR

Financiere des Professionnels Fonds d investissement inc. decreased its holdings in shares of Icon Plc (NASDAQ:ICLR) by 39.2% in the 4th quarter, Holdings Channel reports. The fund owned 29,343 shares of the medical research company’s stock after selling 18,948 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in Icon were worth $5,347,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ICLR. WINTON GROUP Ltd acquired a new position in Icon during the second quarter worth about $254,000. Daiwa Securities Group Inc. raised its stake in Icon by 19.3% during the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after acquiring an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC raised its stake in Icon by 97.6% during the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after acquiring an additional 35,253 shares in the last quarter. Peapack Gladstone Financial Corp acquired a new position in Icon during the second quarter worth about $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Icon by 58.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after buying an additional 289 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ICLR shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $165.00 price objective on shares of Icon in a research note on Friday, May 29th. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, May 29th. Piper Sandler downgraded Icon to a “neutral” rating in a research note on Thursday, May 28th. Royal Bank Of Canada upped their price objective on Icon from $123.00 to $126.00 and gave the company a “sector perform” rating in a research note on Friday, May 29th. Finally, BMO Capital Markets upped their price objective on Icon from $130.00 to $160.00 and gave the company an “outperform” rating in a research note on Friday, May 29th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $156.44.

Icon Stock Performance

NASDAQ:ICLR opened at $144.59 on Thursday. The company has a market capitalization of $11.07 billion, a PE ratio of 23.47, a P/E/G ratio of 11.99 and a beta of 1.26. The company has a 50 day simple moving average of $120.28 and a two-hundred day simple moving average of $140.53. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $211.00.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, June 10th. The medical research company reported $2.52 earnings per share for the quarter, beating analysts’ consensus estimates of $2.47 by $0.05. The business had revenue of $2.11 billion during the quarter, compared to the consensus estimate of $1.99 billion. Icon had a net margin of 5.98% and a return on equity of 9.50%. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.43 EPS. Research analysts anticipate that Icon Plc will post 9.74 earnings per share for the current year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.